ArticleResearch square2025
Loss of M1 Acetylcholine Receptor-mediated Orexinergic Activity Contributes to Immune Dysfunction in Experimental Sepsis.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: Sepsis (life-threatening organ dysfunction caused by a dysregulated host response to infection) causes millions of deaths worldwide annually. Sepsis-induced changes in brain regulatory functions remain understudied. Previous work demonstrated that cecal ligation and puncture (CLP, a murine model of sepsis) affected physiologic variables and serum cytokines and hormone levels. Correction of decreased activity in the orexinergic nervous system or administration of the M1 muscarinic acetylcholine receptor (M1mAChR) agonist xanomeline reversed some of these findings. We hypothesized that these Main Body: Xanomeline reversed CLP-induced loss of orexinergic activity and restored physiologic variables and hormone levels to baseline; these corrections were eliminated by addition of the orexin receptor antagonist almorexant. To examine the effects of system reactivation we developed a transgenic mouse whose orexinergic neurons could be depolarized via a Designer Receptor Exclusively Activated by Designer Drugs (DREADD) and its ligand, clozapine-N-oxide (CNO). Orexinergic re-activation or xanomeline administration reversed CLP-induced changes in TNFa and IL-1b levels; almorexant eliminated xanomeline effects. CNO reversed the effects of CLP on serum levels of IL-6 and KC; this effect was not present after xanomeline administration. G-CSF, a colony stimulating factor, was not affected by either CNO or xanomeline. Both orexinergic activation and xanomeline administration reversed CLP-induced increase in the number of splenic macrophages and monocyte-derived dendritic cells (DCs); almorexant did not affect the response to xanomeline. CLP-induced decreases in the numbers of central DCs, CD4 Conclusion: Decreased orexinergic activity mediates some post-CLP immunologic changes, identifying a previously unrecognized proximal pathogenic mechanism in sepsis. Some, but not all, of these changes result from a loss of M1mAChR-mediated stimulation of orexinergic neurons. These findings suggests that disruption of orexin's central coordinating function is a key, and perhaps causative, component of the dysregulated host response that is the defining characteristic of sepsis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.